It will be interesting to see where companies developing therapeutics based on epigenome editing technology choose to focus their development efforts over the next few years. For Moonwalk Biosciences ...
A new startup co-founded by CRISPR innovator Feng Zhang, a former executive at Grail and Illumina, and others has raised $57 million to develop a defanged form of gene editing that doesn’t cut the DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results